| Deep Vein Thrombosis
Eliquis vs Savaysa
Side-by-side clinical, coverage, and cost comparison for deep vein thrombosis.Deep comparison between: Eliquis vs Savaysa with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSavaysa has a higher rate of injection site reactions vs Eliquis based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Savaysa but not Eliquis, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Eliquis
Savaysa
At A Glance
Oral
Twice daily
Factor Xa inhibitor
Oral
Daily
Factor Xa inhibitor
Indications
- Atrial Fibrillation
- Deep Vein Thrombosis
- Pulmonary Embolism
- Venous Thromboembolism
- Nonvalvular atrial fibrillation
- Deep Vein Thrombosis
- Pulmonary Embolism
Dosing
Atrial Fibrillation 5 mg orally twice daily; 2.5 mg twice daily in patients with at least 2 of the following: age >=80 years, body weight <=60 kg, or serum creatinine >=1.5 mg/dL.
Deep Vein Thrombosis (prophylaxis, hip or knee replacement) 2.5 mg orally twice daily initiated 12-24 hours post-surgery; 35 days for hip replacement, 12 days for knee replacement.
Deep Vein Thrombosis, Pulmonary Embolism (treatment) 10 mg orally twice daily for 7 days, then 5 mg twice daily.
Deep Vein Thrombosis, Pulmonary Embolism (recurrence reduction) 2.5 mg orally twice daily after at least 6 months of treatment for DVT or PE.
Venous Thromboembolism (pediatric) Weight-based dosing orally twice daily following at least 5 days of initial anticoagulant treatment; doses range from 0.3 mg to 10 mg twice daily based on weight tier.
Nonvalvular atrial fibrillation 60 mg orally once daily in patients with CrCL >50 to <=95 mL/min; reduce to 30 mg once daily for CrCL 15-50 mL/min; do not use in patients with CrCL >95 mL/min.
Deep Vein Thrombosis, Pulmonary Embolism 60 mg orally once daily following 5-10 days of initial parenteral anticoagulant therapy; reduce to 30 mg once daily for CrCL 15-50 mL/min, body weight <=60 kg, or concomitant use of certain P-gp inhibitors.
Contraindications
- Active pathological bleeding
- Severe hypersensitivity reaction to apixaban (e.g., anaphylactic reactions)
- Active pathological bleeding
Adverse Reactions
Most common (>=1%) Epistaxis, contusion, hematuria, menorrhagia, hematoma, hemoptysis, rectal hemorrhage, gingival bleeding, nausea, anemia.
Serious Major bleeding including intracranial hemorrhage, gastrointestinal bleeding, and fatal bleeding.
Most common (>=1%) Rash, abnormal liver function tests, anemia
Serious Intracranial hemorrhage, gastrointestinal bleeding, fatal bleeding
Postmarketing Thrombocytopenia, abdominal pain, angioedema, hypersensitivity, dizziness, headache, anticoagulant-related nephropathy, urticaria
Pharmacology
Apixaban is a selective inhibitor of factor Xa (FXa) that does not require antithrombin III for antithrombotic activity; by inhibiting free and clot-bound FXa and prothrombinase activity, it decreases thrombin generation and thrombus development without directly affecting platelet aggregation.
Edoxaban is a selective inhibitor of factor Xa (FXa) that does not require antithrombin III for antithrombotic activity; inhibition of FXa in the coagulation cascade reduces thrombin generation and thrombus formation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Eliquis
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
Savaysa
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (4/12) · Qty limit (9/12)
UnitedHealthcare
Eliquis
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Savaysa
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (4/8)
Humana
Eliquis
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Savaysa
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Eliquis.
No savings programs available for Savaysa.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EliquisView full Eliquis profile
SavaysaView full Savaysa profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.